Risk stratification and patient counseling for natalizumab in multiple sclerosis

Neurology. 2012 Feb 7;78(6):436-7. doi: 10.1212/WNL.0b013e318245d2d0. Epub 2012 Jan 25.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal, Humanized / adverse effects*
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Counseling
  • Humans
  • Multiple Sclerosis / drug therapy*
  • Natalizumab
  • Risk

Substances

  • Antibodies, Monoclonal, Humanized
  • Natalizumab